A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...
American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...
Researchers built a four-gene signature based on propionate metabolism that stratifies colorectal cancer patients by survival ...
Daiichi Sankyo & AstraZeneca’s Datroway approved in China to treat unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy: Tokyo Friday, October ...
Datopotamab Deruxtecan Approved in China for Advanced Triple-Negative Breast Cancer / Africa, Annals of Oncology, Asia, ...
Jefferies reiterated a Buy rating and a USD 56.00 price target for UroGen Pharma stock on September 10, 2026, according to ...
10月6日至8日，癌症早期检测大会（Early Detection of Cancer Conference）在英国举行。艾米森两项肿瘤无创检测研究入选大会壁报展示，分别聚焦尿路上皮癌与结直肠癌，以1mL尿液和10mL血液为样本路径，展示公司基于DNA甲基化技术开展癌症早期检测及复发监测的最新研究进展。艾米森两位创始人张良禄、董兰兰参加本次大会，并与来自全球的临床专家、科研学者及产业代表开展交流。
South Korea has granted national health insurance coverage to a combination therapy involving new drugs from two ...
本屆大會聚焦癌症早期檢測及臨床轉化，涵蓋液體活檢、多癌種早期檢測、癌症早期生物標誌物發現及驗證等前沿議題。艾米森兩位創始人張良祿、董蘭蘭參加大會，並與來自不同國家和地區的科研及臨床專家就相關研究進行交流。
2026年欧洲肿瘤内科学会（ESMO）年会将于当地时间10月23日至27日在西班牙马德里举行。作为全球肿瘤学领域最具影响力的学术盛会之一，ESMO年会将汇聚国际顶尖学者，集中展示肿瘤治疗领域的前沿进展与突破性成果。 本届大会，荣昌生物维迪西妥单抗、RC148、RC118等核心产品共有21项重要研究入选，覆盖胃癌、泌尿肿瘤、乳腺癌、肺癌、卵巢癌、胰腺癌、胆管癌等多个领域。其中，维迪西妥单抗治疗乳腺外 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results